Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Biochemical Recurrence of Malignant Neoplasm of Prostate”

82 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 82 results

Not applicableNot Yet RecruitingNCT06875297
What this trial is testing

A Single-center Prospective Interventional Study on FPG500 in Non-metastatic Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 184
Not applicableLooking for participantsNCT06859203
What this trial is testing

A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET

Who this might be right for
Biochemical Recurrence of Malignant Neoplasm of Prostate
Technical University of Munich 94
Testing effectiveness (Phase 2)Study completedNCT00148772
What this trial is testing

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

Who this might be right for
Prostate Cancer
Endeavor Health 29
Testing effectiveness (Phase 2)Study completedNCT04019964
What this trial is testing

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

Who this might be right for
Prostate CancerRecurrent Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 8
Not applicableStudy completedNCT06204302
What this trial is testing

An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States

Who this might be right for
Non-metastatic Prostate CancerNon-metastatic Castration-resistant Prostate Cancer
Bayer 1,800
Testing effectiveness (Phase 2)Study completedNCT00174863
What this trial is testing

Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer

Who this might be right for
Prostatic Neoplasm
Sanofi 232
Testing effectiveness (Phase 2)Looking for participantsNCT07365423
What this trial is testing

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

Who this might be right for
Recurrent Prostate Cancer
Swiss Cancer Institute 42
Large-scale testing (Phase 3)Study completedNCT00838201
What this trial is testing

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Who this might be right for
CancerCarcinomaCastrate-Resistant Prostate Cancer+2 more
Amgen 384
Early research (Phase 1)Study completedNCT00629057
What this trial is testing

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

Who this might be right for
Androgen-insensitive Prostate Cancer
Bavarian Nordic 24
Large-scale testing (Phase 3)Study completedNCT03389451
What this trial is testing

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

Who this might be right for
Prostate CancerProstatic NeoplasmProstatic Neoplasms, Castration-Resistant+2 more
Michael Graham PhD, MD 30
Testing effectiveness (Phase 2)Study completedNCT05526248
What this trial is testing

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

Who this might be right for
Biochemically Recurrent Prostate Cancer
Bayer 28
Not applicableStudy completedNCT01118741
What this trial is testing

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Not applicableStudy completedNCT03087903
What this trial is testing

Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA

Who this might be right for
Prostate Cancer
University of Colorado, Denver 41
Not applicableLooking for participantsNCT06657131
What this trial is testing

Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

Who this might be right for
Prostate Cancer After a Radical TreatmentBiochemical Recurrence of Malignant Neoplasm of ProstateBiochemical Persistence of Prostate Cancer
Heinrich-Heine University, Duesseldorf 250
Testing effectiveness (Phase 2)Active Not RecruitingNCT04009967
What this trial is testing

Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning

Who this might be right for
Prostate Cancer
CHU de Quebec-Universite Laval 30
Testing effectiveness (Phase 2)Looking for participantsNCT04700332
What this trial is testing

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Who this might be right for
Prostate Cancer
Hoag Memorial Hospital Presbyterian 184
Large-scale testing (Phase 3)Study completedNCT06235099
What this trial is testing

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

Who this might be right for
Prostate CancerProstate AdenocarcinomaBiochemical Recurrence of Malignant Neoplasm of Prostate
Curium US LLC 235
Early research (Phase 1)Active Not RecruitingNCT05077098
What this trial is testing

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Who this might be right for
Recurrent Prostate Cancer
Mark Stein 8
Large-scale testing (Phase 3)Study completedNCT00657904
What this trial is testing

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Who this might be right for
Non-metastatic Prostate Cancer
AstraZeneca 3,618
Large-scale testing (Phase 3)Study completedNCT00089674
What this trial is testing

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Amgen 1,468
Load More Results